参考文献/References:
[1].Fala L. Repatha (Evolocumab):second PCSK9 inhibitor approved by the FDA for patients with familial hypercholesterolemia[J]. Am Health Drug Benefits,2016,9(Spec Feature):136-139.
[2].[]Giunzioni I,Tavori H. New developments in atherosclerosis:clinical potential of PCSK9 inhibition[J]. Vasc Health Risk Manag,2015,11:493-501.
[3].[]Liu C,Lu H,Yuan F,et al. A Phase 1,Randomized,double-blind,single-dose,placebo-controlled safety, tolerability,and pharmacokinetic/pharmacodynamic study of evolocumab in healthy Chinese subjects[J]. Clin Pharmacol,2019,11:145-153.
[4].[]Lee E,Gibbs JP,Emery MG,et al. Influence of renal function on evolocumab exposure,pharmacodynamics,and safety[J].Clin Pharmacol Drug Dev,2019,8(3):281-289.
[5].[]Gibbs JP,Slatter JG,Egbuna O,et al. Evaluation of Evolocumab (AMG 145),a fully human anti-PCSK9 IgG2 monoclonal antibody,in subjects with hepatic impairment[J]. J Clin Pharmacol,2017,57(4):513-523.
[6].[]Tada H,Takamura M,Kawashiri MA. Lipoprotein(a) as an old and new causal risk factor of atherosclerotic cardiovascular disease[J]. J Atheroscler Thromb,2019,26(7):583-591.
[7].[]Carr SS,Hooper AJ,Sullivan DR,et al. Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment[J]. Pathology,2019,51(2):148-154.
[8].[] Julius U,Tselmin S,Schatz U,et al. Lipoprotein(a) and proprotein convertase subtilisin/kexin type?9 inhibitors[J]. Clin Res Cardiol Suppl,2019,14(Suppl 1):45-50.
[9].[]Sun H,Samarghandi A,Zhang N,et al. Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation,irrespective of the low-density lipoprotein receptor[J]. Arterioscler Thromb Vasc Biol,2012,32(7):1585-1595.
[10].[]Toth PP,Jones SR,Monsalvo ML,et al. Effect of Evolocumab on non-high-density lipoprotein cholesterol,apolipoprotein B,and lipoprotein(a):a pooled analysis of phase 2 and phase 3 studies[J]. J Am Heart Assoc,2020,9(5):E014129.
[11].[]Yousuf O,Mohanty BD,Martin SS,et al. High-sensitivity C-reactive protein and cardiovascular disease:a resolute belief or an elusive link?[J]. J Am Coll Cardiol,2013,62(5):397-408.
[12].[] Shapiro MD, Fazio S. PCSK9 and atherosclerosis-lipids and beyond[J]. J Atheroscler Thromb,2017,24(5):462-472.
[13].[]Tang Z,Jiang L,Peng J,et al. PCSK9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-κB activation in THP-1-derived macrophages[J]. Int J Mol Med,2012,30(4):931-938.
[14].[]Koskinas KC,Windecker S,Buhayer A,et al. Design of the randomized,placebo-controlled evolocumab for early reduction of LDL-cholesterol levels in patients with acute coronary syndromes (EVOPACS) trial[J]. Clin Cardiol,2018,41(12):1513-1520.
[15].[]邹新亮,景涛,何国祥. 前蛋白转化酶枯草溶菌素9抑制剂在ACS早期应用前景[J] .临床心血管病杂志,2020,36(4):378-381.
[16].[]Ruscica M,Tokg?zo?lu L,Corsini A,et al. PCSK9 inhibition and inflammation:A narrative review[J]. Atherosclerosis,2019,288:146-155.
[17].[]Sahebkar A,di Giosia P,Stamerra CA,et al. Effect of monoclonal antibodies to PCSK9 on high-sensitivity C-reactive protein levels: a meta-analysis of 16 randomized controlled treatment arms[J]. Br J Clin Pharmacol,2016,81(6):1175-1190.
[18].[]Podrez EA,Byzova TV,Febbraio M,et al. Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype[J]. Nat Med,2007,13(9):1086-1095.
[19].[]Cammisotto V,Pastori D,Nocella C,et al. PCSK9 regulates Nox2-mediated platelet activation via CD36 receptor in patients with atrial fibrillation[J]. Antioxidants (Basel),2020,9(4):E296.
[20].[]Pastori D,Nocella C,Farcomeni A,et al. Relationship of PCSK9 and urinary?thromboxane excretion to cardiovascular events in patients with atrial fibrillation[J]. J Am Coll Cardiol,2017,70(12):1455-1462.
[21].[]Sabatine MS,Giugliano RP,Keech AC,et al. Evolocumab and clinical outcomes in patients with cardiovascular disease[J]. N Engl J Med,2017,376(18):1713-1722.
[22].[]Zafar Y,Sattar Y,Ullah W,et al. Proprotein convertase subtilisin/Kexin type-9 (PCSK-9) inhibitors induced liver injury—a retrospective analysis[J]. J Community Hosp Intern Med Perspect,2020,10(1):32-37.
[23].[]Rosenson RS,Hegele RA,Fazio S,et al. The evolving future of PCSK9 inhibitors[J]. J Am Coll Cardiol,2018,72(3):314-329.
[24].[]Wong ND,Shapiro MD. Interpreting the findings from the recent PCSK9 monoclonal antibody cardiovascular outcomes trials[J]. Front Cardiovasc Med,2019,6:14.
[25].[]Authors/Task Force Members,ESC Committee for Practice Guidelines (CPG),ESC National Cardiac Societies. 2019 ESC/EAS guidelines for the management of dyslipidaemias:Lipid modification to reduce cardiovascular risk[J].
[26].Atherosclerosis,2019,290:140-205.
相似文献/References:
[1]李艳茹,白世茹,李如意,等.PCSK9抑制剂在血脂代谢中的研究进展[J].心血管病学进展,2020,(7):729.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.014]
LI Yanru,BAI Shiru,LI Ruyi,et al.PCSK9 Inhibitors in Lipid Metabolism[J].Advances in Cardiovascular Diseases,2020,(12):729.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.014]
[2]李天瑜 袁晋青.前蛋白转化酶枯草溶菌素9抑制剂与血小板功能[J].心血管病学进展,2021,(1):17.[doi:10.16806/j.cnki.issn.1004-3934.2021.01.000]
LI Tianyu,YUAN Jinqing.Proprotein Convertase Subtilisin/kexin Type 9 Inhibitors and Platelet Function[J].Advances in Cardiovascular Diseases,2021,(12):17.[doi:10.16806/j.cnki.issn.1004-3934.2021.01.000]
[3]石惠薇 热娜提·肉孜 刘硕霖 吴娜琼.高脂蛋白a血症的相关治疗进展[J].心血管病学进展,2021,(4):297.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.003]
SHI Huiwei,Rinat·Rozi,LIU Shuolin,et al.Lipoprotein(a)-lowering Therapy[J].Advances in Cardiovascular Diseases,2021,(12):297.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.003]
[4]林琳 李京秀 闫娜 刘丹阳 查理 金恩泽.脂蛋白a的治疗现状及研究新方向[J].心血管病学进展,2021,(6):543.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.016]
LIN Lin,LI Jingxiu,YAN Na,et al.The Therapeutic Status and Research Prospects of the Treatment of Lipoprotein a[J].Advances in Cardiovascular Diseases,2021,(12):543.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.016]
[5]殷人麟 尤华 郑林.前蛋白转化酶枯草溶菌素9抑制剂与冠状动脉粥样硬化斑块逆转的研究进展[J].心血管病学进展,2022,(8):710.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.011]
YIN Renlin,YOU hua,Zheng Lin?/html>.PCSK9 Inhibitors in?nhibiting Coronary Atherosclerotic Plaque[J].Advances in Cardiovascular Diseases,2022,(12):710.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.011]
[6]许晓宇 唐炯 郑甲林.PCSK9对血管内皮功能影响的研究进展[J].心血管病学进展,2023,(6):551.[doi:10.16806/j.cnki.issn.1004-3934.2023.06.016]
XU Xiaoyu,TANG Jiong,ZHENG Jialin.Research Progress on the Effects of PCSK9 on Vascular Endothelial Function[J].Advances in Cardiovascular Diseases,2023,(12):551.[doi:10.16806/j.cnki.issn.1004-3934.2023.06.016]